STOCK TITAN

If You Invested in Incannex Healthcare Limited (IXHL)

Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ
Looking for the current price? See the IXHL quote & overview
$1,000 invested 1 Year Ago
$184
-81.6% price return
-81.6% with dividends reinvested
Bought on Nov 24, 2025 at $10.08 split-adjusted
$1,000 invested 5 Years Ago
N/A
Our prices start Mar 2, 2022
$1,000 invested 10 Years Ago
N/A
Our prices start Mar 2, 2022

What $1,000 or $10,000 in IXHL Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Mar 2, 2022
$1,000 $184 -82% — — $4.17 -99.58%
$10,000 $1,845 -82% — — $42 -99.58%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-20. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for IXHL

$1,000 Investment Over Time

IXHL vs S&P 500

Year-by-Year Returns

IXHL annual performance
Year Start Price End Price Annual Return Cumulative
2022Mar 2 to Dec 30 $446.40 $84.00 -81.2% -81.2%
2023 $84.00 $139.20 +65.7% -68.8%
2024 $139.20 $63.60 -54.3% -85.8%
2025 $63.60 $10.74 -83.1% -97.6%
2026Dec 31, 2025 to Nov 20 $10.74 $1.86 -82.7% -99.6%

About Incannex Healthcare Limited

Healthcare · NASDAQ

Incannex Healthcare Inc. develops clinical-stage biopharmaceutical programs based on combination therapies and regulated botanical wellness medicine. The company’s common stock trades on Nasdaq under the symbol IXHL. Its business is centered on research and development programs for high-impact medical conditions, with company disclosures emphasizing investigational therapies for obstructive sleep apnea and generalized anxiety disorder.

The company’s lead disclosed program is IHL-42X, an investigational oral fixed-dose combination of dronabinol and acetazolamide designed for the treatment of obstructive sleep apnea. Incannex has described IHL-42X as a therapy intended to target underlying mechanisms of obstructive sleep apnea through the combined activity of its two active pharmaceutical ingredients. The program has been reported with Phase 2 clinical results, and the U.S. Food and Drug Administration has granted Fast Track Designation for IHL-42X.

Incannex also develops PSX-001, an oral fixed-dose synthetic botanical research compound formulation in development for generalized anxiety disorder. The company has reported completed Phase 2 clinical work for PSX-001 and positions the program within its broader development focus on novel therapies for serious mental-health conditions.

Incannex manages its business as one reportable and operating segment focused on research and development involving regulated botanical wellness medicine and therapies. Earlier company materials also describe an Australian license to import, export and distribute medicinal cannabis products, as well as a launched line of cannabinoid products. The company’s current public communications emphasize clinical development, regulatory interaction, capital structure, Nasdaq listing status and financing activities related to its investigational pipeline.

Corporate filings identify Incannex Healthcare Inc. as an emerging growth company and list its common stock as registered on The Nasdaq Stock Market LLC. The company has also disclosed capital-structure actions, including a completed 1-for-30 reverse stock split of its common stock and Nasdaq minimum bid price compliance matters. Its principal office is listed in Melbourne, Australia.

Market Cap
$23.3M
Current Price
$1.86
EPS (FY2026)
-$1.66
Revenue (FY2026)
$0
View full IXHL overview

Frequently Asked Questions

Incannex Healthcare Limited investment returns

How much would $1,000 invested in Incannex Healthcare Limited be worth today?

If you invested $1,000 in Incannex Healthcare Limited (IXHL) 1 year ago on 2025-11-24, your investment would be worth $184 as of 2026-11-20, a -81.6% price return without dividends.

Has Incannex Healthcare Limited outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare IXHL performance over available time periods.

What is Incannex Healthcare Limited's average annual return?

Over the past 1 year, IXHL’s share price returned -81.6%, without dividends. Individual years vary a great deal, and IXHL’s best recent full year was 2023 (+65.7%) while the worst was 2025 (-83.1%).

For informational and educational purposes only, not investment advice.